Effects of mixed ETA and ETB-receptor antagonist (Ro-47-0203) on hepatic microcirculation after warm ischemia
- PMID: 9201101
- DOI: 10.1023/a:1018830929913
Effects of mixed ETA and ETB-receptor antagonist (Ro-47-0203) on hepatic microcirculation after warm ischemia
Abstract
There is evidence that endothelin (ET) is involved in disturbances of the hepatic microcirculation after warm ischemia. In this study we investigated the influence of a mixed ETA-, ETB-receptor antagonist (Bosentan) on ischemia-reperfusion damage of the liver by means of intravital fluorescence microscopy (IVM). Clamping of the left liver lobe (= warm ischemia) was performed in 16 male Wistar rats for 70 min. The treatment group (N = 8) received 15 mg/kg Bosentan (Ro-47-0203) 1 min prior to reperfusion. Controls (N = 8) received an equivalent amount of Ringer's solution. Between 20 and 90 min after reperfusion, leukocyte-endothelial cell interactions in sinusoids and postsinusoidal venules as well as perfusion of hepatic acini were studied. Application of Bosentan improved sinusoidal blood flow, attenuated manifestations of microvascular perfusion failure, and decreased the number of rolling leukocytes in postsinusoidal venules. Our results provide further evidence that ET is involved in postischemic impairment of hepatic microhemodynamics during reperfusion.
Similar articles
-
Postischemic improvement of hepatic microhemodynamics by a mixed ETA-, ETB-receptor antagonist (RO-47-0203).Transplant Proc. 1997 Feb-Mar;29(1-2):1365-6. doi: 10.1016/s0041-1345(96)00598-2. Transplant Proc. 1997. PMID: 9123342 No abstract available.
-
Endothelin receptor blockade as a therapeutic strategy in ameliorating postischemic damage to the liver microcirculation.J Cardiovasc Pharmacol. 2000 Nov;36(5 Suppl 1):S351-3. doi: 10.1097/00005344-200036051-00102. J Cardiovasc Pharmacol. 2000. PMID: 11078418
-
Pharmacological regulation of postischemic sinusoidal diameters in rats--a new approach for reducing hepatic ischemia/reperfusion injury.Clin Hemorheol Microcirc. 2001;24(4):233-46. Clin Hemorheol Microcirc. 2001. PMID: 11564912
-
Effect of the endothelin receptor antagonist bosentan on postischemic liver microcirculation.Zentralbl Chir. 1996;121(9):788-93. Zentralbl Chir. 1996. PMID: 8921579
-
Remodeling of hepatic microvascular responsiveness after ischemia/reperfusion.Shock. 1997 Aug;8(2):80-5. doi: 10.1097/00024382-199708000-00002. Shock. 1997. PMID: 9261896 Review.
Cited by
-
Bosentan, an endothelin antagonist, augments hepatic graft function by reducing graft circulatory impairment following ischemia/reperfusion injury.J Gastrointest Surg. 2001 May-Jun;5(3):322-9. doi: 10.1016/s1091-255x(01)80055-x. J Gastrointest Surg. 2001. PMID: 11360057
-
Hypoxic hepatitis - epidemiology, pathophysiology and clinical management.Wien Klin Wochenschr. 2010 Mar;122(5-6):129-39. doi: 10.1007/s00508-010-1357-6. Wien Klin Wochenschr. 2010. PMID: 20361374 Review.
-
Tezosentan, a novel endothelin receptor antagonist, markedly reduces rat hepatic ischemia and reperfusion injury in three different models.Liver Transpl. 2008 Dec;14(12):1737-44. doi: 10.1002/lt.21621. Liver Transpl. 2008. PMID: 19025917 Free PMC article.
-
Endothelin A receptor blockade reduces hepatic ischemia/reperfusion injury after warm ischemia in a pig model.J Gastrointest Surg. 2003 Mar-Apr;7(3):331-9. doi: 10.1016/s1091-255x(02)00417-1. J Gastrointest Surg. 2003. PMID: 12654557
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials